RECRUITING

Novel Glaucoma Diagnostics

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of this research is to evaluate novel technologies for the assessment of ocular structure and function, including the scanning device called Optical Coherence Tomography (OCT). We will test the OCT and other devices in their ability to image diseases of the eye and also compare the measurements made with OCT to those of other imaging and visual field devices approved by the Food and Drug Administration (FDA). OCT may be useful for the early diagnosis and monitoring of a variety of types of eye diseases

Official Title

Novel Diagnostics for Ocular Structure

Quick Facts

Study Start:2000-08-01
Study Completion:2029-07-31
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT00286637

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Ability to provide informed consent and to understand the study procedures
  2. * Healthy volunteers
  3. * Age related macular degeneration (AMD), diabetic retinopathy, central serous chorioretinopathy, and/or glaucoma or glaucoma suspects
  4. * (AD Sub-Study ONLY): Subjects diagnosed with AD or MCI.
  1. * Any medical treatment (e.g., chronic corticosteroid, hydroxychloroquine, chloroquine, thioridazine, canthaxanthine) or conditions that affect VF (e.g., stroke) and retinal thickness other than glaucoma.
  2. * Strabismus, nystagmus, or any condition that prevents fixation.
  3. * Presence of any media opacities that hinders clinical view of the fundus, and any intraocular non-glaucomatous abnormality
  4. * History of ocular trauma or intraocular surgery other than uncomplicated glaucoma interventions or cataract extraction at least 3 months previous to participating in the study.

Contacts and Locations

Study Contact

Taylor Harwood
CONTACT
215-928-3197
tharwood@willseye.org
Ronald Zambrano
CONTACT
215-928-3197
rzambrano@willseye.org

Principal Investigator

Joel S Schumann, MD
STUDY_CHAIR
Wills Eye Hospital

Study Locations (Sites)

Wills Eye Hospital
Philadelphia, Pennsylvania, 19107
United States

Collaborators and Investigators

Sponsor: Wills Eye

  • Joel S Schumann, MD, STUDY_CHAIR, Wills Eye Hospital

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2000-08-01
Study Completion Date2029-07-31

Study Record Updates

Study Start Date2000-08-01
Study Completion Date2029-07-31

Terms related to this study

Keywords Provided by Researchers

  • OCT
  • CSLO
  • SLP
  • Perimetry
  • electrophysiology
  • glaucoma
  • macular degeneration
  • retinopathy
  • diabetes
  • macular hole

Additional Relevant MeSH Terms

  • Glaucoma
  • Macular Disease